Gland Pharma Limited (GLAND) — Board Meeting | 26 August 2026

· NSE 🟡 Notable Neutral
By StockFin Research Team AI-Assisted Analysis Source: BSE/NSE Filings
📢 Key Event
Gland Pharma's AGM approved FY2026 financials and declared dividend
💡 Investor Takeaway
Shareholders approved key financials and leadership appointments, confirming board continuity and dividend payout.

Gland Pharma's 48th AGM held on August 25, 2026 approved the audited standalone and consolidated financial statements for FY2026, declared a final dividend, and reappointed directors Wenjie Zhang and Wei Huang. All resolutions passed with majority support, including dividend declaration and director reappointments. The meeting was conducted via video conferencing with 119,672 shareholders on record as of August 18, 2026.

📄 View Original Announcement (PDF)

About Gland Pharma Limited (GLAND)

Healthcare · Pharmaceuticals · Listed on NSE

Market Cap: ₹47,316.21 Cr P/E: 41.9 ROE: 10.9% ROCE: 15.2% Div Yield: 0.70%

View full GLAND stock details →

📡 Get AI alerts when GLAND files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track GLAND — Free

📊 More GLAND filings

See all GLAND filings →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when GLAND files new disclosures

Track GLAND filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track GLAND — Free

Free account · 2 AI queries/day